Thrivent Financial for Lutherans Has $672,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Thrivent Financial for Lutherans reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,689 shares of the company’s stock after selling 534 shares during the period. Thrivent Financial for Lutherans’ holdings in Pacira BioSciences were worth $672,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Pacira BioSciences during the 3rd quarter valued at $191,000. Charles Schwab Investment Management Inc. increased its holdings in Pacira BioSciences by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 431,897 shares of the company’s stock valued at $6,500,000 after purchasing an additional 16,819 shares during the last quarter. Quantbot Technologies LP acquired a new position in Pacira BioSciences in the third quarter valued at about $257,000. BNP Paribas Financial Markets boosted its holdings in Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in Pacira BioSciences during the third quarter worth about $493,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $24.89 on Thursday. The company has a fifty day moving average price of $24.89 and a 200 day moving average price of $20.20. The firm has a market cap of $1.15 billion, a PE ratio of -12.26 and a beta of 0.70. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67.

Wall Street Analysts Forecast Growth

PCRX has been the topic of a number of analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays increased their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright raised their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.